C4 Therapeutics, Inc.

Q: Jun 30 2026

Q: Mar 31 2026

FY: Dec 31 2025

Q: Sep 30 2025

Q: Jun 30 2025

Q: Mar 31 2025

FY: Dec 31 2024

Q: Sep 30 2024

Q: Jun 30 2024

Q: Mar 31 2024

FY: Dec 31 2023

Q: Sep 30 2023

Q: Jun 30 2023

Q: Mar 31 2023

FY: Dec 31 2022

Q: Sep 30 2022

Q: Jun 30 2022

Q: Mar 31 2022

FY: Dec 31 2021

Q: Sep 30 2021

Regulation FD Disclosure

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Regulation FD Disclosure

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Results of Operations and Financial Condition

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Entry into a Material Definitive Agreement

Results of Operations and Financial Condition

Regulation FD Disclosure

Results of Operations and Financial Condition

Entry into a Material Definitive Agreement

Other Events

Regulation FD Disclosure

Regulation FD Disclosure

Results of Operations and Financial Condition

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Results of Operations and Financial Condition

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Notice of Effectiveness

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933

Free Writing Prospectus

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Notice of Effectiveness

Registration statement under Securities Act of 1933

Registration statement under Securities Act of 1933

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Notice of Effectiveness

Post-effective amendment to a registration statement

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Automatic Shelf Registration

Prospectus Supplement with Pricing Information

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Anderson Kenneth Carl

GROGAN DONNA ROY

Adams Kendra

Mossler Mark

Geldmacher Jay L

RA CAPITAL MANAGEMENT, L.P.

Lynx1 Capital Management LP

Squadron Capital Management LLC

Mossler Mark

MORGAN STANLEY

Mossler Mark

BlackRock, Inc.

REYNO LEONARD

GROGAN DONNA ROY

Anderson Kenneth Carl

GROGAN DONNA ROY

Anderson Kenneth Carl

Cooper Ronald Harold Wilfred

Bessen Laura

Fawell Stephen

Annual Report Scanned (Paper)

Annual Report Scanned (Paper)

No description available

No description available

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Letter from the SEC

Annual Report Scanned (Paper)

Annual Report Scanned (Paper)

Post-effective amendment to an automatic shelf registration statement

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Draft registration statement (confidential submission)

Correspondence with the SEC

Correspondence with the SEC

No description available

Correspondence with the SEC

No description available